Potency and in vitro tolerance of organic nitrates: Partially denitrated metabolites contribute to the tolerance-devoid activity of pentaerythrityl tetranitrate

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 1, 2007, Pages 68-74

  Koenig, Andreas ^a   Lange, Kathrin ^a   Konter, Joerg ^a   Daiber, Andreas ^b   Stalleicken, Dirk ^c   Glusa, Erika ^a   Lehmann, Jochen ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c Actavis Deutschland GmbH   (Germany)

Author keywords

Bioavailability; Nitrate tolerance; Organic nitrates; Pentaerythrityl tetranitrate; Vasodilation

Indexed keywords

GLYCERYL TRINITRATE; N ACETYL S NITROSOPENICILLAMINE; N PHENYLPIPERAZINONOATE; NITRIC OXIDE DONOR; ORGANIC NITRATE; PENTAERYTHRITYL DINITRATE; PENTAERYTHRITYL MONONITRATE; PENTAERYTHRITYL TETRANITRATE; PENTAERYTHRITYL TRINITRATE; PIPERAZINE DERIVATIVE; PROSTAGLANDIN F2 ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG TOLERANCE; FECES; FEEDING; IN VITRO STUDY; LUNG ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SWINE; VASODILATATION; WISTAR RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; DINOPROST; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; MALE; NITRATES; NITRIC OXIDE DONORS; PENTAERYTHRITOL TETRANITRATE; PULMONARY ARTERY; RATS; RATS, WISTAR; SWINE; VASODILATION; VASODILATOR AGENTS;

EID: 34547702218     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31805881ee     Document Type: Article

References (25)

1. Fink B, Bassenge E. Unexpected, tolerance-devoid vasomotor and platelet actions of pentaerythrityl tetranitrate. J Cardiovasc Pharmacol. 1997;30:831-836.
2. Jurt U, Gori T, Ravandi A, et al. Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: A human in vivo study. J Am Coll Cardiol. 2001;38:854-859.
3. Pfaffenrath V, de la Motte S, Harrison F, et al. Effect of pentaerithritol tetranitrate, isosorbide mononitrate and placebo on the headache and on the ability to work of healthy volunteers. Arzneimittelforschung. 1998;48:646-650.
4. Schwemmer M, Bassenge E. New approaches to overcome tolerance to nitrates. Cardiovasc Drugs Ther. 2003;17:159-173.
5. Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res. 2005;97:618-628.
6. Daiber A, Oelze M, Coldewey M, et al. Oxidative stress and mitochondrial aldehyde dehydrogenase activity: a comparison of pentaerythritol tetranitrate with other organic nitrates. Mol Pharmacol. 2004;66:1372-1382.
7. Chen ZQ, Foster MW, Zhang J, et al. An essential role for mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation. Proc Natl Acad Sci U S A. 2005;102:12159-12164.
8. 2B receptors. Br J Pharmacol. 2000;130:692-698.
9. Decker M, Koenig A, Glusa E, et al. Synthesis and vasorelaxant properties of hybrid molecules out of NO-donors and the betareceptor blocking drug propranolol. Bioorg Med Chem Lett. 2004;14:4995-4997.
10. Konter J, Abou-Rahma El-Din AAH, El-Emam A, et al. The NOtizer - a device for the convenient preparation of diazen-1-ium-1,2-diolates. Methods Enzymol. 2005;396:17-26.
11. Glusa E, Adam C. Endothelium-dependent relaxation induced by cathepsin G in porcine pulmonary arteries. Br J Pharmacol. 2001;133:422-428.
12. Seeling A, Lehmann J. NO-donors, part X [1]: Investigations on the stability of pentaerythrityl tetranitrate (PETN) by HPLC-chemoluminescence-N- detection (CLND) versus UV-detection in HPLC. J Pharm Biomed Anal. 2006;40:1131-1136.
13. Kukovetz WR, Holzmann S. Mechanisms of nitrate-induced vasodilatation and tolerance development. Eur J Clin Pharmacol. 1991;40:103-109.
14. Kojda G, Hacker A, Noack E. Effects of nonintermittent treatment of rabbits with pentaerythritol tetranitrate on vascular reactivity and superoxide production. Eur J Pharmacol. 1998;355:23-31.
15. Hüsgen B, Noack E, Kojda G. Comparison of the vasorelaxing effect of different nitrovasodilators in conductive arterial and venous blood vessels. In: Schrör K, Pace-Asciak CR, eds. Mediators in the Cardiovascular System: Regional Ischemia. Basel: Birkhäuser Verlag; 1995:183-187.
16. Wessler C, Homann A, Fricke U, et al. NO donors, part 8 [1]: synthesis and vasodilating activities of substituted benzylnitrates compared to cyclohexylmethylnitrate and GTN. Eur J Med Chem. 2003;38:581-586.
17. Alheid U, Dudel C, Forstermann U. Selective-inhibition by gossypol of endothelium-dependent relaxations augments relaxations to glyceryl trinitrate in rabbit celiac artery. Br J Pharmacol. 1987;92:237-240.
18. Kojda G, Beck JK, Meyer W, et al. Nitrovasodilator-induced relaxation and tolerance development in porcine vena cordis magna - dependence on intact endothelium. Br J Pharmacol. 1994;112:533-540.
19. Chen ZQ, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci USA. 2002;99:8306-8311.
20. Oberle S, Abate A, Grosser N, et al. Heme oxygenase-1 induction may explain the antioxidant profile of pentaerythrityl trinitrate. Biochem Biophys Res Commun. 2002;290:1539-1544.
21. Davidson IW, Miller HS, Dicarlo FJ. Absorption, excretion and metabolism of pentaerythritol tetranitrate by humans. J Pharmacol Exp Ther. 1970;175:42-50.
22. Davidson IW, Rollins FO, Dicarlo FJ, et al. Pharmacodynamics and biotransformation of pentaerythritol trinitrate in man. Clin Pharmacol Ther. 1971;12:972-981.
23. King SY, Fung HL. Rapid microbial degradation of organic nitrates in rat excreta. Re-examination of the urinary and fecal metabolite profiles of pentaerythritol tetranitrate in the rat. Drug Metab Dispos. 1984;12:353-357.
24. Neurath GB, Dunger M. Blood levels of metabolites of glyceryl trinitrate and pentaerythritol tetranitrate after administration of a two-step preparation. Arzneimittelforschung. 1977;27:416-419.
25. Weber W, Michaelis K, Luckow V, et al. Pharmacokinetics and bioavailability of pentaerithrityl tetranitrate and two of its metabolites. Arzneimittelforschung. 1995;45:781-784.